Document Detail

Newer carbapenems for urinary tract infections.
MedLine Citation:
PMID:  15364304     Owner:  NLM     Status:  MEDLINE    
Four carbapenems have been available clinically in Japan. These are imipenem/cilastatin (IMIP/CS) and panipenem/ betamipron (PANI/BP) of the older compounds and newer carbapenems such as biapem (BIAP) and meropenem (MERO). The latter compounds are relatively stable to dehydropeptidase-1 (DHP-1) and have been reported to have higher antimicrobial activities compared to the earlier carbapenems. The antimicrobial activity of these four carbapenems against fresh urinary isolates showed high activities against Enterobacteriacae such as Serratia marcescens, Enterobacter cloacae, Citrobacter freundii and Escherichia coli containing the class C-beta-lactamase- and extended spectrum beta-lactamase (ESBL)-producing strains compared to piperacillin (PIPC) and ceftazidime (CTAZ). Against Pseudomonas aeruginosa, the carbapenems, with the exception of panipenem showed strong antimicrobial activities compared to PIPC and CTAZ. High activities were also seen against Enterococcus faecalis, Staphylococcus aureus and Staphylococcus epidermidis, but methicillin-resistant strains were not affected. The first generation carbapenems showed better activity against E. faecalis than newer carbapenems. All four carbapenems were similar in clinical effectiveness in double blind trials for complicated urinary tract infections (UTIs). However, PANI/BP is less effective in UTIs caused by P. aeruginosa than IMIP/CS. MERO showed better eradication rate of P. aeruginosa than IMIP/CS. Retrospective analysis of treated cases using carbapenems showed a rapid defervescence in the treatment of febrile complicated UTIs, which were mainly caused by mixed infection of Gram-negative and Gram-positive bacteria, especially those involving P. aeruginosa and E. faecalis.
Tetsuro Matsumoto; Tetsuro Muratani
Related Documents :
19763644 - In vitro activities of moxifloxacin and tigecycline against bacterial isolates associat...
16542604 - Bacteriological agents of neonatal sepsis in nicu at nishtar hospital multan.
1867074 - Neonatal sepsis in pakistan. presentation and pathogens.
1909714 - False resistance to imipenem with a microdilution susceptibility testing system.
25182484 - Anti-mrsa-acting carbamidocyclophanes h-l from the vietnamese cyanobacterium nostoc sp....
16490334 - Evaluation of multiple genetic markers for typing drug-resistant mycobacterium tubercul...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  International journal of antimicrobial agents     Volume:  24 Suppl 1     ISSN:  0924-8579     ISO Abbreviation:  Int. J. Antimicrob. Agents     Publication Date:  2004 Sep 
Date Detail:
Created Date:  2004-09-14     Completed Date:  2005-02-01     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9111860     Medline TA:  Int J Antimicrob Agents     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  S35-8     Citation Subset:  IM    
Department of Urology, School of Medicine, University of Occupational and Environmental Health, 1-1, Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Bacterial Agents / chemistry,  pharmacology*
Bacteria / drug effects*
Bacterial Infections / drug therapy*,  microbiology
Carbapenems / chemistry,  pharmacology*
Double-Blind Method
Enterobacteriaceae / drug effects
Gram-Positive Cocci / drug effects
Microbial Sensitivity Tests
Pseudomonas aeruginosa / drug effects
Randomized Controlled Trials as Topic
Urinary Tract Infections / drug therapy*,  microbiology
Urine / microbiology
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Carbapenems

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Urinary tract infections in African infants.
Next Document:  New drugs for Gram-positive uropathogens.